Individualizing Frontline Treatment Decisions in EGFR-Mutant NSCLC

This segment explores how treatment decisions for EGFR-mutant non-small cell lung cancer (NSCLC) are increasingly individualized despite the availability of combination frontline therapies. Drs. Mark Socinski and Susan Scott discuss the continued role of osimertinib monotherapy, emphasizing that treatment selection should be guided by shared decision-making, patient preferences, comorbidities, treatment goals, and tolerance for potential adverse effects. Dr. Scott explains that although she discusses combination regimens with nearly all eligible patients, a meaningful proportion ultimately choose osimertinib alone because of lower-risk disease or concerns about additional toxicity. Dr. Socinski reinforces this perspective by sharing a long-term clinical experience with a patient who has maintained a durable complete response on osimertinib monotherapy for several years. Together, they highlight the importance of balancing clinical efficacy with quality of life and recognizing that monotherapy remains an appropriate option for carefully selected patients within the evolving treatment landscape of EGFR-mutant NSCLC.